- Calliditas Therapeutics - Year-End Report 2019
- Positive Opinion Received From EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the Treatment of IgAN
- Calliditas Submits Draft Registration Statement for the Listing of ADSs in the U.S.
- The pivotal Phase 3 Clinical Trial NefIgArd Part A Fully Recruited
- Completion of Recruitment of Part A of the Neflgard Pivotal Phase 3 Clinical Trial by Year End
- China IND Approval Triggers $5 Million Milestone Payment From Everest Medicines
Calliditas Therapeutics AB (CALTX:STO) closed at 113.60, -8.83% below its 52-week high of 124.60, set on Feb 07, 2020.
39.95Mar 08 2019124.60Feb 07 2020
|Market cap||4.40bn SEK|
|EPS (TTM)||-3.60 |
Data delayed at least 15 minutes, as of Feb 14 2020 17:00 GMT.